Centric Wealth Management’s AbbVie ABBV Stock Holding History

Centric Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,300	Closed	-$308K	–	154
2021 Q4	$308K	Hold	2,300	–	–	0.1%	121
2021 Q3	$13K	Sell	2,300 -900	-28%	-$103K	﹤0.01%	151
2021 Q2	$19K	Hold	3,200	–	–	0.01%	147
2021 Q1	$19K	Buy	3,200 +2,000	+167%	+$214K	0.01%	210
2020 Q4	$5K	Buy	+1,200	New	+$115K	﹤0.01%	206

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centric Wealth Management's ABBV Position: Q1 2026 in Review

Centric Wealth Management reduced its AbbVie (ABBV) stake by 0.57% in Q1 2026, selling an estimated $35.7K and leaving 27,968 shares worth $5.82M. The position accounts for 1.16% of the portfolio, ranked #18.

Centric Wealth Management first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.35M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Centric Wealth Management held 27,968 shares of AbbVie worth $5.82M as of Q1 2026.
Centric Wealth Management sold 161 AbbVie shares in Q1 2026, an estimated $35.7K.
AbbVie made up 1.16% of Centric Wealth Management's portfolio in Q1 2026, its #18 holding.
Centric Wealth Management first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
Centric Wealth Management's AbbVie position peaked at $6.35M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Centric Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.